ViyaSH Scientific unit to buy Bioforlife Italia for EUR16.975m

Viyash Scientific Ltd., a global integrated pharmaceutical enterprise operating across API, human health, animal health, and CDMO sectors, has announced plans to acquire Bioforlife Italia for EUR16.975 million. The transaction, which is expected to strengthen Viyash’s presence in the animal health market, aligns with the company’s strategy to expand its end-to-end capabilities. This follows a strategic merger between SeQuent Scientific and Viyash Lifesciences in March 2025, which aimed to create a global animal health leader with integrated capabilities. The acquisition of Bioforlife Italia underscores Viyash Scientific’s continued focus on consolidating its market position and enhancing its portfolio through strategic acquisitions. Investors are likely to view the move as a step toward long-term growth and operational diversification. The deal is subject to regulatory approvals and customary closing conditions.